Characteristics | Total (n = 505) | cHCC-CC (n = 35) | HCC (n = 419) | CC (n = 51) | p value |
---|---|---|---|---|---|
Male | 404 (80.0) | 28 (80.0) | 343 (81.9)b | 33 (64.7) | 0.015 |
Age (years) | 61 (32–87) | 57 (37–79)a | 62 (32–87) | 60 (33–85) | 0.211 |
Hypertension | 208 (41.2) | 16 (45.7) | 178 (42.5)b | 14 (27.5) | 0.102 |
Diabetes Mellitus | 119 (23.60 | 3 (8.6)a | 102 (24.3) | 14 (27.5)c | 0.085 |
Smoking | 208 (48.6) | 27 (47.4) | 87 (20.8) | 8 (15.7) | 0.695 |
Alcohol use | 102 (20.2) | 7 (20.0) | 74 (17.7) | 4 (7.8)c | 0.043 |
HBV positive | 227 (45.0) | 15 (42.9) | 186 (44.4) | 26 (51.0) | 0.649 |
HCV positive | 124 (24.6) | 8 (22.9) | 98 (23.9) | 18 (35.3) | 0.171 |
Total Bilirubin | 0.95 ± 0.42 | 0.93 ± 0.32 | 0.95 ± 0.42 | 0.94 ± 0.46 | 0.982 |
Albumin | 4.1 ± 0.3 | 4.0 ± 0.3 | 4.1 ± 0.3 | 4.2 ± 0.2 | 0.308 |
INR | 1.04 ± 0.07 | 1.03 ± 0.04 | 1.04 ± 0.07 | 1.05 ± 0.12 | 0.451 |
Cirrhosis | 163 (32.3) | 12 (34.4) | 145 (34.6)b | 6 (11.8)c | 0.004 |
Child–Pugh class A | 489 (96.8) | 35 (100) | 403 (96.5) | 51 (100) | 0.399 |
Edmondson–Steiner Grades, I–II | 322 (63.7) | 18 (51.4) | 292 (69.6)b | 12 (23.5) | 0.404 |
Tumor size | 5.3 ± 3.3 | 5.8 ± 2.1 | 5.2 ± 3.4 | 5.3 ± 2.4 | 0.623 |
Tumor size ≥ 5 cm | 225 (45.2) | 24 (68.6)a | 178 (42.5)b | 23 (52.3) | 0.007 |
Tumor number (≥ 2) | 51 (10.2) | 3 (8.6) | 46 (11.0) | 2 (4.5) | 0.385 |
AFP (ng/mL) ≥ 200 | 91(21.3) | 8 (22.9) | 115 (27.4)b | 3 (5.9)c | 0.003 |
ICG% | 11.1 ± 7.9 | 10.7 ± 5.5 | 11.3 ± 8.3 | 9.6 ± 5.5 | 0.359 |
Operative margin > 1 cm | 361 (71.4) | 25 (71.4) | 306 (73.0)b | 30 (58.8)c | 0.003 |
Major hepatectomy | 257 (50.8) | 19 (54.2) | 203 (48.4)b | 35 (68.6)c | 0.007 |
Microvascular invasion | 152 (30.1) | 13 (37.1) | 131 (31.3)b | 8 (15.7)c | 0.047 |
Macrovascular invasion | 72 (14.3) | 5 (14.3) | 66 (15.8)b | 1 (2.0)c | 0.029 |
Lympho nodules metastasis | 20 (4.0) | 7 (20.2)a | 5 (1.2)b | 8 (15.7) | < 0.0001 |
Distal metastasis | 10 (2.0) | 0 (0) | 7 (1.7)b | 3 (5.9) | 0.086 |
AJCC stage, I–II | 383 (75.8) | 27 (77.1) | 320 (76.3)b | 36 (70.5) | < 0.0001 |
Antiviral therapy | 282 (55.8) | 18 (51.4) | 239 (57.0) | 25 (49.0) | 0.168 |
Recurrence | 135 (26.7) | 9 (25.7) | 120 (28.6)b | 6 (11.8) | 0.036 |
Recurrence per 100 person-years | 33.7 | 42.1 | 38.5b | 25.3 | < 0.0001 |
Mortality | 149 (29.5) | 14 (40.0)a | 108 (25.8)b | 27 (52.8) | < 0.0001 |
Mortality per 100 person-years | 94.1 | 104.1a | 86.7b | 113.8 | < 0.0001 |
Follow-up times (months) | 38 (1–94) | 31 (4–75)a | 40 (1–94)b | 26 (1–85) | < 0.0001 |